



CURRICULUM VITAE as of March 2006

Name : Laurence ZITVOGEL

Education :

1981 B.A University Pierre et Marie Curie, Pitié Salpêtrière Faculty
1987 M.D Pitié Salpêtrière Medical School, Paris 13
1992 M.D Thesis St Louis Hospital, Paris 10

Post doctoral Training :

Internship and Residencies :

1984-1985 : Intern in Medicine, Pitié Salpêtrière Hospital, Paris V
1985-1986 : Junior Assistant Resident, Neurology and Internal Medicine, Pitié Salpêtrière Hospital
1986-1987 : Senior Assistant resident , Internal Medicine, Surgery, Pitié Salpêtrière Hospital

Clinical and Research Fellowships :

1987-1988 : Clinical Fellow in Emergency Care Unit, Internal Medicine, University West Paris
1988-1989 : Clinical Fellow in Surgery, and Internal Medicine, University Paris V, VII, XI Hospitals, Paris
1989-1990 : Clinical Fellow in Haematology, Paris VI, XI Hospitals, Paris
1990-1991 : Research Fellow, Division of Tumor Immunology, Institut Curie, Paris
1991-1992 : Clinical Fellow in Oncology, Paris VI, VII, XI Hospitals, Paris
1992-1995 : Research Associate, University of Pittsburgh, Biomedical Science Tower, Departement of Molecular and Cellular Biology (MT Lotze's lab.)
1995-1997 : Clinical Assistant Professor, Translational Immunotherapy Unit, Institut Gustave Roussy, Villejuif
1997-2006: Attending in the clinic, Consulting, Breast Cancer Department, IGR, Villejuif

Licensure and Certification :

1981 : Pitié Salpêtrière Medical School License
1987 : French Board of Internal Medicine
1992 : French Board of Medical Oncology, subspecialty : Immunology
1995 : American Certificate of Research in Immunology, Pittsburgh
1997 : Faculty Clinical Certificate of Kremlin Bicêtre, subspecialty : Medical Oncology
1998 : Research Habilitation, Kremlin Bicêtre Faculty
2003: Full Professor in Immunology, Biology, Kremlin Bicêtre Faculty, University Paris XI

Academic Appointments :

1992-1995 : Instructor in Medical Oncology, University Paris VII
1995-2003 : Assistant Professor of Medical Oncology, University Paris XI
2003-2006: Full Professor, Biological Immunology, University Paris XI

Hospital Appointments :

1992-1995 : Junior Associate in Immunotherapy, MT Lotze's Immunotherapy Unit, Pittsburgh Cancer Institute, Pennsylvania, USA
1995-1997 : Assistant Physician, Translational Immunotherapy Unit, Institut Gustave Roussy, Villejuif
1997-2003 : Associate Physician, Breast Cancer Department, Institut Gustave Roussy, Villejuif
2003-2006: Associate Professor of Immunology, Dept of Clinical Biology and Attending in Breast Cancer Department IGR, Villejuif and Affiliate Medical Staff in Melanoma and Immunotherapy Unit as well as Cell Therapy Unit , IGR.

Research Appointments :

1998 : Habilitation to direct Research
2002 : Head of INSERM Unit, Methodological and Translational Innovative Research. Title of ERM0208 INSERM : « Role of dendritic cells and their exosomes in the regulation of lymphocyte effector functions ».
2002: Funding support by LIGUE LABELISEE CONTRE LE CANCER 1
2004: Director of the Center of Clinical Investigations in Biotherapies IGR/Curie
2005: Director of U805 INSERM
2005-2008: Funding support by LIGUE LABELISEE CONTRE LE CANCER 2

Awards and Honors :

1981: Bachelor, high grade score
1991: Degree of Medical Statistics, with specific score.
1992: Gold Medal, Internal medicine
1992: **Selection for The Scientific and Medical Vocation by Fondation Bleustein Blanchet**
1994: Presidential Award at the 9th meeting of the Society for Biological Therapy, Napa Valley, California
1995: **Merit Award**, American Society of Clinical Oncology, Los Angeles
1995: PhD defense with Congratulations and specific honors
1996: **PRICE of caritative Ligue Française Contre le Cancer**, Haute Loire
1999: **PRICE of Chancellerie**, Gustave Roussy, Sorbonne, Paris
2000 : **PRICE of the Academy of Medicine**
2004: **PRICE Charles OBERLING of the Academy of Medicine**

Major Committee Assignments :

National and Regional :

1996-2002 : Club Francophone of Dendritic Cells
2001- : Expert in Committee of INSERM (French Research Institute for Health)
1997- : Scientific Committee of Ministry of Health
2001-2009 : Committee of Fondation de France
2003- 2004 : Partner in INSERM Committee
2006-2009: Member of the comitee for Fondation pour la Recherche Médicale

International :

1997 : EORTC, New Treatment Committee
2004: The Oncologist, review Board

Memberships in Professional Societies :

1995: American Society of Clinical Oncology
1995: American Association of Immunologists

- 1996: American Association for Cancer Research
 1996: European Society of Medical Oncology

Major Research Interests :

31. Immunotherapy of cancer
32. Immunobiology and dendritic cells (DC, IKDC)
33. Immunobiology of exosomes
34. Functional characterization of NK cells
35. Antitumor immunity in mouse models
36. Effector mechanisms of allogeneic bone marrow transplantation
37. New prognosis factors in breast cancer (TLR3, TLR4, chemokines): immunogenetics

Current Research Funding Information :

- 1996, 1998, 2002 : Association for Cancer Research (France) : DC and exosomes in tumor immunity.
 2000 : Transfusion and Research Society
 Bone Marrow Transplantation Society for the Role of NK cells in allogeneic transplantation.
- 1998, 2000 : LIGUE Française contre le Cancer. Role of NK and NKT cells in antitumor immune responses.
- 1999-2001 : Private Biotechnology Company : APCells, Anosys on the work on exosomes and exosome based-clinical trial (Phase I)
- 1998-2000 : Contract with Aventis for adenoviral vector based-clinical trials
- 2001-2005 : EC QoL-2001-00093 (5th EC programm project grant) on the role of exosomes as a potent cancer vaccine.
- 2002-2005 : INSERM funding : research on the biology of dendritic cells, NK cells and tumor immunity.
- 2002-2005 : French Ministry of Health (National PHRC) : Second Phase I clinical trial with exosomes in melanoma
- 2002-2005 : Label of the ERM0208 INSERM from the LIGUE Française contre le Cancer for research on the biology of dendritic cells, NK cells and tumor immunity.**
- 2000-2001 : Salary for a post doc by the Ministry of Foreign Affairs (Yoshi Ikarashi)
- 2001-2002 : Salary for a post doc by the Ministry of Foreign Affairs (Rumiko Mikami)
- 2001-2002 : Salary for a post doc. Position « Foreign fellows ARC » (Koji Maruyama)
- 2002-2003 : Salary for a post doc. Position « Wellcoming Position INSERM » (Julien Taieb)
- 2002-2003 : Salary for a post doc. Position « Green Position INSERM » (Koji Maruyama)
- 2004-2008: Contractant in the 6th EC framework program “ALLOSTEM” coordinated by A. Madrigal
- 2004-2008: Contractant in the 6th EC framework program “DC THERA” coordinated by J. Austyn
- 2004-2006: Grant allocated by NOVARTIS on the immunomonitoring of GIST patients treated with Gleevec
- 2004-2006: Grant allocated by ABSciences on the immunomonitoring of cancer patients treated with AB1010
- 1-0 Grant INCa on Regulation of functions of regulatory T cells (D. Klatzmann, coordinator)
- 2-0 Grant INCa on Immunogenicity of apoptosis in cancer (S. Amigorena, coordinator)
- 3-0 Grant INCa on NKp30 polymorphism in GIST tumors
- 1-0 Grant INCa on Phase II/III randomized trial using autologous exosomes in non operable lung cancer patients (Stage IIIb/IV)
- 2-0 Private Donation (Mrs Badinter): Phase II/III randomized trial using autologous exosomes in non operable lung cancer patients (Stage IIIb/IV)
- 2006-2009 : Renewal Labeling by LIGUE Française contre le Cancer for research on the biology of dendritic cells, NK cells, IKDC and tumor immunity.**
- 2006-2010: Renewal Labeling INSERM as U805**
- 2005-2008: Center of Clinical Investigation (15 000 euros)**

Consulting

APCells/Anosys: Scientific Advisory Board

Cell Therapy Unit Pr Klatzmann and Pr Lemoine
Cell Therapy Unit Pr M. Adams, Cardiff
Guava Cie (phone expert)
NanoDimension AG (Zurich, site visit and review of files)

Reviewer

Ad Hoc Reviewer *Nature Medicine*
Ad Hoc Reviewer *Nature Biotechnology*
Ad Hoc Reviewer *Journal of Immunology*
Ad Hoc Reviewer *Journal of Immunotherapy*
Ad Hoc Reviewer *Cancer Research*
Ad Hoc Reviewer *International Journal of Cancer*
Ad Hoc Reviewer *Human Gene Therapy*
Ad Hoc Reviewer *Journal of Hepatology*
Ad Hoc Reviewer *Leukemia*
Ad Hoc Reviewer *Eur. Cytokine Network*
Ad Hoc Reviewer *Journal of Experimental Medicine*
Ad Hoc Reviewer *J. Leukocyte Biology*
Ad Hoc Reviewer *Gene Therapy*

Patents :

1998 : IGR/INSERM/CNRS/CURIE: exosomes as a novel way to sensitize dendritic cells for vaccines , Filing N° 98 01437 , 1998

1999 : IGR: Activation of NK cells by dendritic cells, filing N° 98 02558, 1999

2001 : IGR : Immunogenic vesicles in biological fluids, filing N° 0110179 on 07/2001

2002 : IGR : Targeted Inhibition of tyrosine kinases in immunomodulation, filing N° 02 11545 on 09/02: PCT patent application is WO04026311 (publication date : 2004-04-01).

Teaching Experience :

1995-1999 : Instructor, OncoImmunology course, Medical Faculty
1999-2003 : DEA, PhD Thesis, University Degrees, DESS, DESC, European Schools...

University Degrees

Diplôme universitaire de Thérapie Cellulaire de C. Dosquet/JP Marolleau, Hôpital St Louis. Méthode d'obtention des cellules dendritiques: application dans l'immunité adoptive tumorale.

DU Immunologie IGR: Cellules présentatrices d'antigènes: des bases précliniques aux applications thérapeutiques. Pr T. Tursz,

D.U Pharmacologie Clinique, Pr Marty et Pr Calvo, Fac. Lariboisière, cours annuel sur les "Biothérapeutiques innovantes vaccinales"

D.U "Thérapeutiques Immunologiques" organisé par Hervé Fridman et M. Kazatchkine

D.U Cancérologie F. Goldvasseur et Pr Misset, Paul Brousse

D.U "Thérapeutiques Immunologiques" organisé par Hervé Fridman et M. Kazatchkine

D.U Cancérologie F. Goldvasseur et Pr Misset, Paul Brousse

DESC

Oncologie Médicale IGR : Présentation de l'Antigène et conception de vaccins antitumoraux: thérapie génique utilisant des cytokines régulatrices et cellules dendritiques pulsées.

DEA

-Immunologie : DEA "*Bases Génétiques et Moléculaires du système immunitaire normal et pathologique*" Hôpital Necker. Pr JF BACH. Université Paris V. Immunothérapie des cancers: cytokines et antigènes de tumeurs.

-Biotechnologie Pr Beuzard : Université Paris VII, Immunothérapie des tumeurs par cellules dendritiques. Introduction au Flt3L.

-Relation Hôte Greffon Pr Hervé et Riffle : en transplantation d'organes et greffe de tissus. Hôpital du Bocage, Dijon. Méthode d'obtention des cellules dendritiques: application dans l'immunité adoptive tumorale.

-Cancérologie Pr Tursz

-Bases Fondamentales d'Oncogénèse Pr Sigaux

-DEA d'Endocrinologie, Anne Mantel, Kremlin Bicêtre

Certificates

Certificat d'Oncologie Médicale, Pr Marty, Option Immunologie, Faculté Lariboisière. *Immunothérapie des tumeurs par cellules dendritiques. Introduction au Flt3L.*

Masters LMD

Immunologie Paris XI Pr Galanaud
Paris V, VI, VII Dr Fridman/Sautès

Maîtrise de Biochimie, Jussieu, Paris VII, module d'Immunologie:

IL-12, signaux de costimulation lymphocytaires, et cellules dendritiques: vers des vaccins antitumoraux capables d'améliorer le priming.

Maîtrise de Sciences Biologiques et Humaines, Pr Misset, Paul Brousse, Immunité antitumorale

IFSBM, IGR, Dr Migliarina

European Societies

Hematology

Oncology

Dermatology

Séminaires d'Immunodermatologie, Lyon, Dr JF Nicolas

Séminaires de formation en Immunothérapie, Dr Mayordomo et Dr Trés, Zaragoza, Espagne

Cours d'Immunodermatologie Viennois, ESDR Jan deVries à Montpellier en 1999

Cours d'Immunologie d'Amsterdam

Ateliers de formation INSERM

Thérapie Cellulaire et génique (2002, La Roche Posay)

EPHE JF Jeannin

Journées de formation francophones d'immunologie et immunothérapies des cancers

Dijon

Post Doctoral teaching

Médecins généralistes, Longjumeau : Thérapie Génique en 1996. Des vecteurs, des gènes, des études précliniques et des essais cliniques.

Director of PhD defenses:

Nadine Fernandez 1998, Paris
Joseph Wolfers, l'An 2000, Paris
Anne Lozier, 2001, Paris
Miriam Merad, 2001, Paris
Nathalie Chaput (Thesis of Pharmacy) 2004, Paris
Magali TERME 2004
Nathalie CHAPUT (Thesis of Research Sciences, PhD) 2004
Christophe BORG 2005
Nöel Schartz 2005
Fabrice ANDRE 2005
François GHIRINGHELLI, 2005
EPHE: Caroline Flament 2004

Reports of PhD defenses:

Carole Masurier 1998, Paris
Bernard Bonnotte, 1998, Dijon
Frédéric Geissmann, 1999, Paris
Nathalie Fournier, 2000, Lyon
Hélène Vincent Schneider, 2001, Paris
Jean Sebastien Blanchet, 2001, Toulouse
Frédéric Bérard, 2002, Lyon
Vassili Soumelis, 2003, Necker
Nicolas Larmonier, 2004, Dijon
Karine Laulagnier, 2004, Toulouse
Sophie Paczesny, Paris, 2005
Elise Lavergne, Paris, 2005
Aurélie Trenado, Paris, 2005
Sonia FEAU, 2004, Toulouse
Nathalie JONCKER, 2005, Curie
Benjamin Besse, IGR, Bicêtre, 2005

Reports of Habilitation to direct research (HDR) :

Sarah Boudaly, Paris, 2004
José Cohen, Pitié Salpêtrière, 2004, CERVI, Labo. D. Klatzmann
Guy Gorochov, Pitié Salpêtrière, 2003, Labo. Dr Debré
Jean-Charles Soria, IGR, 2005
Christophe Caux, Lyon Sud, 2003
Nathalie BLIN, 2005, Curie
Frédéric GEISSMAN, 2005, Necker
Jacques Zimmer, Mai 2006, Strasbourg
Franck Pagès, HEGP Paris, Mai 2006
Vassili Soumelis, Curie, Paris, 2006

Clinical and Hospital Service Responsibilities

1994-1995 : Assistant to the P.I MT Lotze : Phase I Gene Therapy using recombinant autologous fibroblasts encoding IL-12 in metastatic cancer. University of Pittsburgh and Pittsburgh Cancer Institute.
1995 Co-PI : Phase II of vaccination of metastatic melanoma with direct intralesional injection of GM-CSF
1997-2000 : Co-PI Adenoviral gene therapy encoding B Galactosidase in unresectable lung cancers
1996-2003 : collaboration on the multicentric trials of the Ludwig Institute using tumor peptides for metastatic melanoma
1999-2001 : participation in the dendritic cell clinical trials (PI Biotech IDM, France)
2000-2002 : Co-PI for the first Phase I based on exosome immunization in metastatic melanoma
2005-2008: Co-PI for the Phase II/III trial: vaccination of stage IIIb/IV NSCLC patients by autologous dendritic cell derived-exosomes
2005-2007: Co-PI for the first Phase I trial combining Gleevec and IL-2 in ovarian cancer resistant to CDDP, to GIST resistant to STI571, to hepatocarcinoma (collaboration with Novartis Pharma in negociation)

Investigational New Drug Applications, FDA and French Regulatory Affairs

1993-1994 : MT Lotze, Pittsburgh. Phase I gene therapy trial.

1999-2000 : with Anosys Inc. FDA and ASSFAPS Exosome based vaccination

BIBLIOGRAPHY

Publications during the Post Doc. In Pittsburgh, USA

1. Zitvogel L., Tahara H., Cai Q., Robbins P.D., Storkus W.J., Muller G., Wolf S.F, Gately M.K., Lotze M.T. Construction and characterization of retroviral vectors expressing biologically active human IL-12. *Hum. Gene Ther.*, 5:1493-1506, 1994.
2. Tahara H., Zitvogel L., Storkus W.J., Zeh III H.J., McKinney T.G., Schreiber R.D., Gubler U., Gately M.K., Robbins P.D., Lotze M.T. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. *J.Immunol.* 154: 6466-6474, 1995.
3. Zitvogel L., Tahara H., Robbins P.D., Storkus W.J., Clarke M., Nalesnik M., Gately M.K., Lotze M.T. Cancer immunotherapy of established tumors with Interleukin-12 (IL-12): Effective delivery by genetically engineered fibroblasts. *J.Immunol.* 155: 1393-1403, 1995.
4. L. Zitvogel, P D.Robbins , M. R.Clarke, R D.Schreiber, C.G Davis , M. J.Maeurer, R.L.Campbell, H.Tahara and M.T.Lotze. B7.1 costimulation markedly enhances IL-12 mediated antitumor immunity *in vivo*. *Eur. J. Immunol.* 26: 1335-1341, 1996.
5. Maeurer M.J., Zitvogel L., Elder E., Storkus W.J., and M.T. Lotze. Human intestinal Vd1+ T cells obtained from patients with colorectal carcinoma respond exclusively to SEB, but not to SEA. *Nat. Immunity*, 14: 188-197, 1996.
6. Maeurer, M.J., Walter W., Martin D.M., Zitvogel L., Elder, E., Storkus W.J., and M.T Lotze. IL-7 in colorectal cancer: IL-7 is produced by tissue from colorectal cancer and promotes preferential expansion of tumor infiltrating lymphocytes. *Scand. J. Immunol.* 45: 263-270, 1997
7. Maeurer, M.J., Martin D.M., Walter, W., Liu, K., Zitvogel L., Haluszczak., C., Rabinowitch H., Duquesnoy, R., Whiteside T.L., Storkus W.J., and M.T Lotze. . Human intestinal Vd1+ T lymphocytes recognize tumor cells of epithelial origin. *J.Exp.Med.* ,183: 1681-1696, 1996.
8. Zitvogel L., Corey S., Maeurer M.J., M.T Lotze and A. Donnerberg. IL-4 induced apoptosis of a gd +T cell leukemia in vitro. The basis of the use of IL-4 systemic administration in T cell leukemia. *Soumis Leukemia*
9. Zitvogel, L., Mayordomo, J.I., T.Tjandrawan, Clarke, M.R., DeLeo A., Lotze, M.T., & Storkus, W.J. 1996. Therapy of murine tumors with tumor derived peptide pulsed dendritic cells : dependence on T cells, B7 costimulation and Th1-associated cytokines. *J.Exp. Med.* 183: 87-97.
10. Mayordomo, J.I., Zorina, T., Storkus, Zitvogel, L., W.J., Celluzzi, C., Falo, L.D., , Melief, C.J., Ildstadt, S.T., Kast, W.M., DeLeo, A.B, & Lotze, M.T. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic anti-tumour immunity. *Nature Medecine*, 1: 1297-1302.
11. Zitvogel, L., Couderc B., Mayordomo, JI, Robbins, PD, Lotze, MT., Storkus WJ. IL-12 engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. *Ann. New York Acad.Sci.* 795:284-293, 1996.
12. Tahara H., M.T. Lotze, Robbins, PD, Storkus, WJ., Zitvogel L. 1995. IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. *Hum. Gene Ther* 6: 1607-1624.

Publications (1997-2002)

1. Maeurer, M.J., Walter W., Martin D.M., Zitvogel L., Elder, E., Storkus W.J., and M.T Lotze. IL-7 in colorectal cancer: IL-7 is produced by tissue from colorectal cancer and promotes preferential expansion of tumor infiltrating lymphocytes. *Scand. J. Immunol.* 45: 263-270, 1997 .
2. Gahery-Segard H, Molinier-Frenkel, V, La Boulaire C, Saulnier, P, Opolon, P, Lengagne, R, Gautier, E, Le Cesne, A, Zitvogel, L., Venet, A, Schatz, C, Courtney, M, Le Chevalier, T, Tursz, T, Guillet, JG, Farace, F. Phase I trial of recombinant adenovirus gene transfer in lung cancer: longitudinal study of the immune responses to transgene and viral products. *J. Clin. Invest.* 100:2218-2226,1997.
3. Myers JN; Mank Seymour A; Zitvogel L.; Storkus W; Clarke M; Johnson CS; Tahara H; Lotze MT . Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. *Laryngoscope*, Feb, 108:2, 261-8, 1998.
4. Couderc, B., Zitvogel, L., Douin-Echinard, Djennane L, Tahara, H., Favre, G., Lotze, MT, Robbins, PD. Enhancement of antitumor immunity by expression of CD70 or CD154 costimulatory molecules in tumor cells. *Cancer Gene Therapy*, 5, 163-175, 1998.
5. Zitvogel, L., Regnault A, Lozier, A, Wolfers J, Flament C, Tenza D, Raposo, G., Amigorena, S. Dendritic cell-derived exosomes elicit potent antitumour immune responses *in vivo*. *Nature Medicine* 4: 594-600, 1998.
6. Fernandez, N., Maraskovsky, E., Perricaudet M., Zitvogel, L. Dendritic cells directly trigger NK cell functions: a cross-talk relevant in innate antitumor immune responses *in vivo*. *Nature Med.* 5, 405-411, 1999.
7. Théry C, Regnault, A, Garin, J, Wolfers, J, Zitvogel L., Ricciardi-Castagnoli P, Raposo G, Amigorena, S. Molecular characterization of DC derived-exosomes: selective accumulation of the heat shock protein hsc 73. *J. Cell. Biol.* 147 (3) : 599-610, 1999.
8. Zitvogel L., Fernandez N, Lozier A, Wolfers J, Ricciardi-Castagnoli P, Regnault A, Amigorena S. Dendritic cells and derivatives for cancer immunotherapy. Dublin Meeting Report on GM-CSF. *Eur. J. Cancer*, 35 pp36-38, 1999.
9. L. Zitvogel, Eric Angevin, T. Tursz. Dendritic cell based-immunotherapy of cancer. *Annals of Oncology* 11 (3) : 199-205, 2000.
10. Merad M, Angevin E., Wolfers J, Flament C., Lorenzi, I, Triebel F, Escudier, B, Zitvogel L. Generation of monocyte -derived DC from renal cell cancer patients: modulation of their functional properties following therapy with biological response modifiers. *J. Immunother.* 23 (3): 369-378, 2000.
11. Wolfers J, Lozier A, Raposo G, Flament . C. Regnault A., Faure F., Tursz T, Angevin E., Amigorena S. Zitvogel L. Tumor-derived exosomes are a source of tumor rejection antigens efficient in CTL cross priming. *Nature Medicine*, 7: 297-303, 2001.
12. Ikarashi Y., Bendelac A, Tursz T, Lemonnier F, Wakasugi H, Zitvogel L. Dendritic cell maturation overrules H-2D-mediated NKT cell inhibition: a critical role of B7 in CD1d-dependent NKT cell Th1 Polarization. *J. Exp. Med.* 194 (8) : 1179-86, 2001.
13. Motta I., André F., Lim A, Tartaglia J, Cox WI, Zitvogel L., Angevin E., Kourilsky P. Cross presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. *J. Immunol* 167 : 1795-1802, 2001.
14. Valteau Couanet D, Maincent K, Leboulaire C , Hartmann O, Beaujean F, Zitvogel L., Angevin E. Dendritic cells for NK/LAK activation :rationale for multicellular immunotherapy in neuroblastoma patients. *Blood*, 100 (7) : 2554-61, 2002.
15. Fernandez N, Angevin E., Flament C., Vivier E, Zitvogel L. Dendritic cells for NK/LAK activation : A cell to cell contact promoting enhancement of NK cell functions. *Eur. Cyt. Network* 13 (1) , 17-27, 2002.
16. André F, Andersen M, Wolfers J, Lozier A, Raposo G, Serra V, Ruegg , Flament C, Angevin E, Amigorena S, Zitvogel L. Exosomes in cancer immunotherapy : preclinical data. *Adv. Exp. Med. Biol.* 2001 ; 495 : 349-54.

17. Zitvogel L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. *J. Exp. Med. Commentary* 2002 Feb4, 195 (3) : F9-F14.
18. André F, Scharz N.E, Movassagh M., Flament C., Pautier P, Morice P, Pomel C, Lhommé C, Escudier B, Le Chevalier T, Tursz T, Amigorena S, Raposo G, Angevin E, Zitvogel L. Malignant effusions and immunogenic tumor derived-exosomes. *The Lancet*,360 :295-305, 2002.
19. Nathalie Chaput, Noël E.C.Scharz, Fabrice André, Julien Taieb, S. Novault, P. Bonnaventure, N Aubert, J. Bernard, François Lemonnier, Myriam Merad, G Adema, M Adams, M Ferrantini, AF Carpentier, B Escudier, T Tursz, Eric Angevin, L. Zitvogel. Exosomes as potent cell free peptide based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. *J. Immunol.* 2004 ; 172 : 2137-2146.
20. Fabrice André, Nathalie Chaput, Noël E.C.Scharz, Caroline Flament, N Aubert, J. Bernard, François Lemonnier, Graça Raposo, B Escudier, Di Hwei Hsu, T Tursz, S. Amigorena, Eric Angevin, L. Zitvogel. Exosomes as potent cell free peptide based vaccine. I. Dendritic cell derived-exosomes transfer functional MHC class I/peptide complexes to Dendritic cells. *J. Immunol.* 2004 ; 172 : 2126-36.
21. Di-Hwei Hsu, Pedro Paz, Gilbert Villafior, Alberto Rivas, Eric Angevin, Laurence Zitvogel, Jean-Bernard Le Pecq. Exosomes Derived from Human Dendritic Cells Transfer MHC Class I and Class II Peptide Complexes to Antigen Presenting Cells. *J. Immunother.* 2003, 26: 440-50.
22. N Chaput, Andre F, Scharz NE, Flament C, Angevin E, Escudier B, Zitvogel L. Exosomes and antitumor immunotherapy. *Bull Cancer* 2003; 90: 695-8. (french).
23. Borg C, Taieb J, Terme M; Maruyama K, Flament C, Angevin E, Zitvogel L. NK cell based-immunotherapy: new prospects and involvement of dendritic cells. *Bull Cancer* 2003; 90: 699-705 (french).
24. F. André*, A. Dunant^f, J. Y. Blay[#], O. Haller^{§§}, I. Treilleux[#], N. Chaput*, L. Zelek^o, M. Spielmann^o, S. Lebecque[¶], Pascale Chomarar^{**}, Anna K. Palucka^{**}, Jacques Banchereau^{**}, Marie C. Mathieu[§] and L. Zitvogel*. Infiltration of Poor Prognosis Breast Tumors With CD123+ Dendritic Cells and Long Term Survival : a Case Control Study. *Submitted.*
25. Mojgan Movassagh^{1,5}, Alain Spatz^{1,5}, Jean M. Davoust^{1,6}, Valérie Velasco¹, Mikaël Pittet², Donata Rimoldi², Danièle Liénard², Laurent Ferradini³, Caroline Robert, Marie-Françoise Avril¹, Serge Lebecque⁴, Laurence Zitvogel¹ and Eric Angevin¹. Selective accumulation of mature DC-Lamp+ Dendritic Cells in tumor sites is associated with local disease control in melanoma. *Cancer Research* 64 : 2192-2198, 2004.
26. Christophe Borg*[¶], Magali Terme*[¶], Julien Taieb*, Caroline Flament*, Eric Angevin*, Kris Thielemans⁺⁺, Bernard Escudier*, Axel LeCesne[#], Véronique Scott*, Isabelle Tchou*, Florent Crépineau*, François Lemoine^{oo}, Jacky Bernard^{**}, Ali Turhan^o, Carlos Ardavin^{##}, Jean-Yves Blay[§], Salah Mécheri⁺, Thomas Tursz*, and Laurence Zitvogel*. Novel mode of action of c-kit tyrosine kinase inhibitors: dendritic cell-mediated-NK cell activation and antitumor effects. *J. Clin. Invest.* 114: 379-388, 2004.
27. Magali Terme*, Elena Tomasello[§], Koji Maruyama*, Florent Crépineau*, Caroline Flament*, Jean-Pierre Marolleau[§], Eric Angevin*, Erwin F. Wagner[#], Benoît Salomon[¶], François Lemonnier⁺, Marco Colonna^{**}, Eric Vivier[§], Laurence Zitvogel*. IL-4 Confers NK Stimulatory Capacity to DC : a Signaling Pathway Involving KARAP/DAP12-TREM2 receptors. *J Immunol.* 2004; 172: 5957-66.
28. Terme M, Borg C, Guilhot F, Masurier C, Flament C, Wagner EF, Caillat-Zucman S, Bernheim A, Turhan AG, Caignard A, Zitvogel L. BCR/ABL promotes dendritic cell-mediated natural killer cell activation. *Cancer Res.* 2005 Jul 15;65(14):6409-17.
29. Escudier B, Dorval T, Chaput N, Andre F, Caby MP, Novault S, Flament C, Leboulaire C, Borg C, Amigorena S, Boccaccio C, Bonnerot C, Dhellin O, Movassagh M, Piperno S, Robert C, Serra V, Valente N, Le Pecq JB, Spatz A, Lantz O, Tursz T, Angevin E, Zitvogel L.. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. *J Transl Med.* 2005 Mar 2;3(1):10.

30. Borg C, Jalil A, Laderach D, Maruyama K, Wakasugi H, Charrier S, Ryffel B, Cambi A, Figdor C, Vainchenker W, Galy A, Caignard A, Zitvogel L. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. *Blood*. 2004 Nov 15;104(10):3267-75. Epub 2004 Jul 8.
1. N. Chaput, Taieb J, Scharzt NE, Andre F, Angevin E, Zitvogel L. Exosome-based immunotherapy. *Cancer Immunol Immunother* 2004; Jan 16.
 2. Julien Taieb, Koji Maruyama, Christophe Borg, Magali Terme, Laurence Zitvogel. Imatinib mesylate impairs Flt3L-mediated NK cell activation and antitumor effects in vivo. *Blood*,2004; 103: 1966-67.
 3. Hegmans JP, Bard MP, Hemmes A, Luider TM, Kleijmeer MJ, Prins JB, Zitvogel L, Burgers SA, Hoogsteden HC, Lambrecht BN. Proteomic analysis of exosomes secreted by human mesothelioma cells. *Am. J. Pathol.* 2004; 164: 1807-15
 38. François Ghiringhelli^{1,2}, Cédric Ménard¹, Magali Terme¹, Caroline Flament¹, Julien Taieb¹, Nathalie Chaput¹, Pierre Emmanuel Puig², Sophie Novault¹, Bernard Escudier³, Eric Vivier⁴, Axel Leacesne⁵, Caroline Robert⁵, Jean-Yves Blay⁶, Jacky Bernard⁷, Sophie Caillat-Zucman⁸, Antonio Freitas⁹, Thomas Tursz¹, Oriane Wagner-Ballon¹⁰, Claude Capron¹⁰, William Vainchenker¹⁰, François Martin², Laurence Zitvogel¹. CD4⁺CD25⁺ T Regulatory Cells Inhibit NK Cell Functions in a transforming growth factor-β-dependent manner. *J Exp Med*. 2005 Oct 17;202(8):1075-85.
 39. François Ghiringhelli¹, Pierre E. Puig¹, Stephan Roux,² Arnaud Parcellier¹, Elise Schmitt¹, Eric Solary¹, Guido Kroemer³, François Martin¹, Bruno Chauffert¹ and Laurence Zitvogel². Tumor Cells Convert Immature Myeloid Dendritic Cells into TGF- Secretors that Stimulate the Proliferation of CD4⁺CD25⁺ Regulatory T Cells. *J Exp Med*. 2005 Oct 3;202(7):919-29. Epub 2005 Sep 26.
 6. Noel EC. Scharzt*†, Nathalie Chaput*, Magali Terme*, Céleste Lebé†, Anneliese Schimpl^o, Julien Taieb*, Laurence Zitvogel*. IL-2 Production by Dendritic Cells is not Critical for the Activation of Cognate and Innate Effectors in Draining Lymph Nodes . *Eur. J. Immunol.* 2005 sep 14 epub ahead of print.
 40. Julien Taieb, Nathalie Chaput, Cédric Ménard, Lionel Apetoh, Marie Péquignot, Noelia Casares, Magali Terme, Caroline Flament, Koji Maruyama, Paule Opolon, Yann Lecluse, Didier Métivier, Elena Tomasello, Eric Vivier, François Ghiringhelli, François Martin, David Klatzmann, Thierry Poynard, Hideo Yagita, Bernard Ryffel, Guido Kroemer and Laurence Zitvogel. A Novel Dendritic Cell Subset involved in Tumor Immunosurveillance. *Nat Med*. 2006 Feb;12(2):214-9. Epub 2006 Jan 29.
 8. Zitvogel L and Tursz T. In vivo veritas. *Nat. Biotech.* 2005; 23: 1372-74.
 9. Taieb J, Chaput N, Scharzt N, Roux S, Novault S, Menard C, Ghiringhelli F, Terme M, Carpentier A, Darrase Jèse G, Lemonnier F, Zitvogel L. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based-vaccines. *J Immunol* 2006; 176: 2722-9.
 10. Casares N, Péquignot M, Tesnière A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas Stbbs S, Obeid M, Coutant F, Métivier D, Pichard E, Aucouturier P, Pierron G; Garrido C, Zitvogel L, Kroemer G. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. *J. Exp. Med.* 2005; 202: 1691-701.

Reviews

1. Robbins P.D., Tahara H., Mueller G.M., Hung G., Banhson A., Zitvogel L., Galea-Lauri J., Ohashi T., Patrene K., Boggs S.S., Evans C.H., Barranger J.A., M.T.Lotze.1994. Retroviral vectors for use in human gene therapy for cancer, Gaucher disease, and arthritis, in *Gene Therapy for Neoplastic Diseases, Annals of the New York Academy of Sciences*, vol.716,p72-89.
2. Robbins P.D., Hung G.L., Tahara H., Galea-Lauri J., Mueller G.M., Zitvogel L., Jaffurs L., McCauley D., Gao W., Huang G., Lotze M.T., C.H Evans.1994. Gene Therapy for arthritis and cancer. *Cancer Gene Therapy*, in press.
3. L.Zitvogel and M.T. Lotze. "Role of IL-12 as an antitumor agent: experimental biology and clinical applications". *Res. Immunol.* 1995, 146: 628-638.

4. Mayordomo J.I., Zitvogel, L., Tjandrawan T., Lotze, M.T., Storkus, W.J. 1995. Dendritic Cells presenting tumor peptide epitopes stimulate effective anti-tumor CTL *in vitro and in vivo*. *In press in IOS, Melanoma Res.*
5. Zitvogel, L., Storkus, W.J., Mayordomo, J.I., Robbins, P.D., Tahara, H., Lotze, MT. Specific Active Immunotherapy of breast cancer: from Gene Therapy Using Regulatory Cytokines (IL-12) and Costimulatory Molecules (B7.1) to the Utilization of Tumor-peptide pulsed-Dendritic Cells. Preclinical Studies and Clinical Trials. Recent advances in Breast Cancer, Hindsgavl, Funen, Denmark, *Scandinavian Breast Group*, Ed. Carsten Rose p55, 1996.
6. Zitvogel L., Pardoux, C, Chouaïb S. Bases fondamentales et rôle de l'IL-12 dans l'hématopoïèse. *Hématologie*, 2: 387-95, 1996.
7. Zitvogel and Lotze, MT. Cancer gene therapy using regulatory cytokines (IL-4 and IL-12) and costimulatory molecules to elicit specific antitumor immune responses. The Biotherapy of Cancers. Editions INSERM, Editor S. Chouaïb, 1998. pp475-494.
8. Thomas F and Zitvogel L. Gene Therapy in the treatment of cancer. *Scrip Magazine* Feb. 1997, 39-43.
9. Mayordomo, JI, Zorina, T, Storkus, WJ, Zitvogel, L. Garcia-Prats, MD, DeLeo, AB, Lotze, MT. Bone-marrow derived DC serve as potent adjuvants for peptide-based antitumor vaccines. *Stem Cells* 1997; 15: 94-103.
10. L. Zitvogel and T. Tueting. BookChapter in Dendritic Cells. Biology and Clinical Applications. Edited by Michael T. Lotze and Angus W. Thomson. Academic Press. London. *Dendritic Cell Genetic Engineering*. 1998.
11. N. Fernandez, MT Duffour, H. Haddada, M. Perricaudet, MT Lotze and L. Zitvogel. Active Specific T cell based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with Dendritic Cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects. . *Cytokines , Cellular and Molecular Therapy* 4:53-65, 1998.
12. Wolfers J, Zitvogel L. Les cellules dendritiques: biologie cellulaire et applications thérapeutiques. *Croissance*, Décembre 1997, pp4-8.
13. Zitvogel, L. A. Regnault, A. Lozier, G. Raposo, S. Amigorena. Dendritic cell-derived exosomes: potent immunogenic cell-free vaccines. Chapter 36. In *Dendritic cells: Biology and Clinical Applications*.
14. L. Zitvogel et F. Faure. Immunité antitumorale: des concepts au transfert en thérapeutique. *Médecine/Sciences*,15: 939-49 1999.
15. L. Zitvogel, N. Fernandez, A. Le Cesne, Angevin E., Farace F, T. Tursz et B. Escudier. Vaccins antitumoraux: Cellules dendritiques et Transfert de Gènes par vecteurs adénoviraux dans les tumeurs. *Chapitre de livre "Thérapie Génique"*, A. Kahn, O. Haguenaer.
16. Regnault A., Raposo G, Amigorena S., Zitvogel L. Immunothérapie antitumorale par les exosomes de cellules dendritiques. *Médecines/Sciences* 1998: 14, 826-7.
17. Wolfers J, Lozier A, Fernandez N, Zitvogel L. L'immunité active spécifique antitumorale: concepts, limites et perspectives. Séminaire 1999. *Immunodermatologie*, John Libbey, Eurotext. JF Nicolas, J. Thivolet eds., chap 8, 109-126, 1999
18. Angevin E., André F, Zitvogel L. L'immunothérapie cellulaire antitumorale: la percée des cellules dendritiques. *Bull Cancer* 2000: 87, 107-115.
19. Fernandez N, Lozier A, Flament C , Zitvogel L. Rôle des cellules dendritiques dans l'immunité naturelle. *Rev. Fr.Allergol.* 1999, 39: 237-239
20. N. Fernandez, L Zitvogel. *Dendritic Cells*. Handbook. Academic Press, SanDiego, CA. 2nd Edition by MT Lotze and A. Thomson. Chap. 18. NK cells. pp245-255, 2001.

21. C. Thery, and L. Zitvogel. *Dendritic Cells*. Handbook. Academic Press, SanDiego, CA. 2nd Edition by MT Lotze and A. Thomson. Chap. 13. DC derived-exosomes. pp 179-187, 2001.
22. André F. L. Zitvogel. Le point sur les cellules dendritiques en immunothérapie antitumorale. *Biotech. Médecine*, N°14, p 12-17, 1999.
23. André F. Angevin E, Escudier B, Le Chevalier T, LeCesne A, Griscelli F, Tursz T, Zitvogel L. Thérapie génique en cancérologie: résultats, enseignements et perspectives. *Revue de presse d'Oncologie Clinique*, p195-201, 2000.
24. André F. Angevin E, Escudier B, Tursz T, Zitvogel L. *Thérapie génique en cancérologie*: Chapitre de livre JF Morère Ed. , sous presse.
25. L. Zitvogel, Andre F. Angevin E, Escudier B, Tursz T. Dendritic cell based-immunotherapy of cancer and acellular vaccines. B. Charpentier Ed. *Transplantation Meeting*. In press
26. L. Zitvogel, G. Raposo, S. Amigorena. Vaccins contre le cancer acellulaires: les exosomes de cellules dendritiques. *Pour la Science*. Oct 2000, 110-111.
27. Masurier Carole, Fernandez Nadine, Lozier Anne, Maraskovsky Eugene, Zitvogel Laurence. Rôle des Cellules dendritiques dans la modulation des fonctions NK. *Hématologie*, 6: 226-233, 2000.
28. André F. Andersen MH, Wolfers J, Lozier A, Raposo G, Amigorena S, Zitvogel L. Exosomes for cancer vaccination. *EFIS Meeting*, Poznan, Poland. 2000. Bookchapter, in press.
29. Terme M ; Masurier C, Fernandez N, Flament C, Lacassagne MN, Marolleau JP, Zitvogel L. Dialogue entre cellules dendritiques et cellules NK. *Congrès Club Francophone des Cellules dendritiques* 1999. Pathologie Biologie, 49 : 475-477, 2001.
30. Zitvogel L, Lozier A, Wolfers J, Raposo G, Amigorena S, Angevin E. Les exosomes véhiculent des antigènes de rejet tumoaux vers les cellules dendritiques : une nouvelle immunothérapie des cancers. *Hématologie*, en préparation.
31. Pierre Guermonprez, Jenny Valladeau, Laurence Zitvogel, Clotilde Théry and Sebastian Amigorena: Antigen presentation and T cell stimulation by dendritic cells. *Annual Review in Immunology*, 2002, Vol 20 : p621-667.
32. Servet C, Zitvogel L, Hosmalin A. Dendritic cells in innate immune responses against HIV. *Curr Molecular Medicine*, 2002 ; 2 : 739-56.
33. André F, Chaput N, Scharz NE, Zitvogel L. Tumor derived-exosomes as a source of tumor antigens. *Vaccine*, 20 :A28-A31, 2002.
1. Scharz NEC, Chaput N, André F, Zitvogel L. From the antigen-presenting cell to the antigen presenting vesicle : the exosomes. *Curr Opin Mol. Ther.* 4 : 372-381, 2002.
 2. Théry C, Zitvogel L, Amigorena S. Exosomes : composition, biogenesis and function. *Nature Review Immunol.* 2 : 569-579, 2002.
 3. L. Zitvogel, N Casares, MO Péquignot, N Chaput, ML Albert, G Kroemer. The immune response against dying tumor cells. *Adv in Immunol.* 84: 131-179, 2004.
 4. N. Chaput, Scharz NE, Andre F, Zitvogel L. Exosomes for immunotherapy of cancer. *Adv. Exp Med Biol* 2003 ; 532 : 215-21.
 5. N. Chaput, NEC Scharz, F. André, L. Zitvogel. Exosomes for immunotherapy of cancer. Handbook of Cancer Vaccines. Edited by MA Morse, TM Clay, HK Lyerly. *Humana Press Inc. Totowa, NJ. Chap. 22. pp331-340. 2004.*
 6. Andre F, Escudier B, Angevin E, Tursz T, Zitvogel L. Exosomes for cancer immunotherapy. *Ann Oncol.* 2004;15 Suppl 4:iv141-4.

7. Navabi H, Croston D, Hobot J, Clayton A, Zitvogel L, Jasani B, Bailey-Wood R, Wilson K, Tabi Z, Mason MD, Adams M. Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. *Blood Cells Mol Dis.* 2005 Sep-Oct 35: 149-52.
8. Taieb J, Chaput N, Zitvogel L. Dendritic cell-derived exosomes as cell-free Peptide-based vaccines. *Crit Rev Immunol.* 2005;25(3):215-23.
42. Chaput N, Taieb J, Scharz N, Flament C, Novault S, Andre F, Zitvogel L. The potential of exosomes in immunotherapy of cancer. *Blood Cells Mol Dis.* 2005 Sep-Oct 35: 111-5.
43. Chaput N, Taieb J, Andre F, Zitvogel L. The potential of exosomes in immunotherapy. *Expert Opin Biol Ther.* 2005 Jun;5(6):737-47.
44. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural killer cells and dendritic cells: "l'union fait la force" *Blood.* 2005 Oct1, 106: 2252-8.
45. Walzer T, Dalod M, Vivier E, Zitvogel L. *NK-DC cross talk in the initiation of immune responses.* *Expert Opin Biol Ther* 2005: Sep 5 (Suppl 1): S49-S59.
46. Ghiringhelli F et Zitvogel L. Melanoma immunotherapy. *Med. Sci.* 2006; 22: 183-187.
47. Zitvogel L, Terme M, Borg C, Trinchieri G. DC-NK cell cross talk: regulation and pathophysiology. *Curr Top Microbiol Immunol* 2006; 298: 157-74.